Market Overview

AgeX Therapeutics CEO Michael D. West to Give Special Interview for The Economist's Conference "The Business of Longevity: Health Innovation for an Ageing World" October 27 in Hong Kong


AgeX Therapeutics, Inc. (AgeX),
a subsidiary of BioTime,
. (NYSE:BTX), announced today that Chief Executive
Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is
giving an interview as part of The Economist magazine's
conference, "The
Business of Longevity: Health Innovation for An Ageing World
," on
Friday, October 27 in Hong Kong.

In a session titled "Special Interview: The Science of Ageing," Dr. West
will be interviewed by Charles Goddard, editorial director Asia Pacific
from The Economist Intelligence Unit, about the current state of
longevity research and development. The session descriptor follows:

"There is much excitement about the next big breakthroughs in
longevity science, which will come in such areas as tissue engineering,
the application of machine learning to biological data, and halting the
ageing process with stem cells and gene therapy. But when are those
breakthroughs likely to occur? In this interview, a leading thinker will
explore the scientific and medical innovations that could extend human
life even further

About AgeX Therapeutics

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to
cellular immortality and regenerative biology to aging and age-related
diseases. The company has three initial areas of product development:
pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular
progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial
planned indications for these products are Type 2 diabetes, cardiac
ischemia, and cancer respectively. For more information, please visit
or connect with the company on Twitter
or Facebook.

About BioTime

BioTime is a late stage clinical biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company's current clinical programs are targeting three
primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its
clinical programs are based on two platform technologies: pluripotent
cells, which can become any type of cell in the human body, and
cell/drug delivery. Renevia®, a cell delivery product, met its primary
endpoint in an EU pivotal trial for the treatment of facial lipoatrophy
in HIV patients earlier this year. Submission for approval of Renevia®
is expected later this year, with an anticipated commercial launch in
2018. OpRegen®, a retinal pigment epithelium transplant therapy, is in a
Phase I/IIa multicenter trial for the treatment of dry age-related
macular degeneration, the leading cause of blindness in developing
countries. BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (NYSE:AST)
and OncoCyte Corporation (NYSE:OCX), and a private company,
AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit or
connect with the company on TwitterLinkedInFacebookYouTube,
and Google+.

To receive ongoing BioTime corporate communications, please click on the
following link to join the Company's email alert list:

View Comments and Join the Discussion!